Briefly blocking a key molecule when administering the only approved vaccine for tuberculosis vastly improves long-term protection against the devastating disease in mice, researchers from Texas Biomedical Research Institute report this week in the Journal of Immunology.
Medication against the nonhuman primate version of HIV given two weeks after infection helped keep tuberculosis in check.
Sequencing more than 170,000 single cells from animal models have provided exceptionally detailed insight into the early immune response to SARS-CoV-2 in the lungs. The findings will help inform future treatment options for the current pandemic and future coronaviruses.
A Zika virus vaccine candidate is effective at preventing the Zika virus passing from mother to fetus in preclinical animal studies, according to a new study in the journal npj Vaccines. The research is a collaboration between Trudeau Institute, Texas Biomedical Research Institute’s Southwest National Primate Research Center (SNPRC), and Walter Reed Army Institute of Research (WRAIR), where the vaccine was developed.
For decades, no one really knew how the drug praziquantel treated a parasitic disease afflicting more than 200 million people around the world. Now, two independent teams of researchers have found the answer, which could help lead to improved treatments that support the W.H.O.’s goal of eliminating Schistosomiasis as a public health problem by 2025.
A new study from Texas Biomedical Research Institute (Texas Biomed) and collaborators has identified a promising drug candidate to minimize uncontrolled, erratic muscle movements, called dyskinesia, associated with Parkinson’s disease.
As widely-anticipated decisions about COVID-19 vaccine boosters roll out from U.S. agencies today, insights from an independent study underscore why boosters are important for all adults.
Four San Antonio research institutes are collaborating to develop treatments against Nipah virus before it spreads. The World Health Organization has named Nipah virus a priority disease in need of urgent research and development because no approved vaccines or treatments exist.
Ian Cheeseman, Ph.D., and his collaborators can now sequence the genomes of individual parasites found in the blood of infected patients -- even when the infection burden is very low, which can occur during asymptomatic infections. Gaining this incredibly detailed view is expected to help develop more effective treatments, vaccines or therapies.
A version of SARS-CoV-2, the virus that causes COVID-19 disease, has been successfully modified to glow brightly in cells and animal tissues, providing a real-time way to track the spread and intensity of viral infection as it happens in animal models.
Risk for heart disease does not look the same on the genetic level for different population groups, report an international team of researchers this month in the journal JAMA Cardiology. The study, led by Texas Biomedical Research Institute (Texas Biomed) and Columbia University Mailman School of Public Health, begins to outline gene activity patterns that could serve as early warning indicators for cardiovascular disease.
AAALAC, the international organization setting the gold standard for research animal care and use, has continued full accreditation status for SNPRC and Texas Biomed, citing dedicated staff and "extremely well cared for animals."
Researchers at Texas Biomedical Research Institute (Texas Biomed) have narrowed down the proteins enabling SARS-CoV-2 to cause disease. Using advanced genetic engineering techniques developed at Texas Biomed, they systematically deleted the genetic code for five of the virus’s accessory proteins, one at a time, to see how each one affected the virus’s ability to spread and cause illness. The research was published online this month in the Journal of Virology.
Scientists have a general idea of how viruses invade and spread in the body, but the precise mechanisms are actually not well understood, especially when it comes to Ebola virus. Olena Shtanko, Ph.D., a Staff Scientist at the Texas Biomedical Research Institute (Texas Biomed), has received more than $1 million from the National Institutes of Health (NIH) to explore different aspects of Ebola virus infection.
The Southwest National Primate Research Center (SNPRC) at Texas Biomed has been awarded more than $37 million from the National Institutes of Health to continue operations into 2026. The P51 grant, given by the NIH Office of Research Infrastructure Programs, provides essential funding to house and care for nearly 2,500 non-human primates that are part of life-science research programs at Texas Biomed and partners around the globe.
The work performed by dozens of scientists at Pfizer, BioNTech, Texas Biomed, the SNPRC and scientific partners around the world from April to July of 2020 is now published in the scientific journal Nature. In the paper titled “Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2” published on Feb. 1, 2021, scientists noted that the vaccine candidate tested for Pfizer “protected the lower respiratory tract from the presence of viral RNA and with no evidence of disease enhancement.”
Texas Biomedical Research Institute received two Department of Defense (DoD) Defense Health Agency subcontracts, totaling nearly $2 million, to assess the efficacy of surface coating and aerosolized decontamination technologies to combat SARS-CoV-2 on surfaces and in the air.
Researchers at the Southwest National Primate Research Center (SNPRC) at Texas Biomedical Research Institute (Texas Biomed) may have found a new pathway to treat and control tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb). Using single-cell RNA sequencing (scRNAseq), a next-generation sequencing technology, scientists were able to further define the mechanisms that lead to TB infection and latency.
A $1.2. million challenge grant from the Mabee Foundation brings Texas Biomedical Research Institute (Texas Biomed) closer to its goal of $10 million to fund the construction of its Nonhuman Primate Animal Facility (NHP ALFA) on its campus. The Institute is more than halfway to its goal. This project will accommodate the critical need of the Southwest National Primate Research Center (SNPRC) to provide innovative, contemporary accommodations and laboratory space for animals involved in research that aid in testing the safety and efficacy of new and improved diagnostics, therapies and vaccines at a larger scale.
Texas Biomedical Research Institute Associate Professor Corinna Ross, PhD, is a principal investigator on a $3.38 million National Institutes of Health multi-investigator grant to study “microbiome-mediated therapies for aging and healthspan” in marmosets, which are small monkeys native to South America and are becoming increasingly more important in aging and infectious disease research. Dr. Ross is partnering with University of Texas at Austin College of Pharmacy Assistant Professor Kelly Reveles, PharmD, PhD.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right